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AbstrAct
Objective Late diagnosis of Alzheimer’s disease (AD) may 
be due to diagnostic uncertainties. We aimed to determine 
the sequence and timing of the appearance of established 
early signs and symptoms in people who are subsequently 
diagnosed with AD.
Methods We used systematic review methodology to 
investigate the existing literature. Articles were reviewed 
in May 2016, using the following databases: MEDLINE, 
PsycINFO, CINAHL, British Nursing Index, PubMed 
central and the Cochrane library, with no language 
restriction. Data from the included articles were extracted 
independently by two authors and quality assessment was 
undertaken with the quality assessment and diagnostic 
accuracy tool-2 (QUADAS tool-2 quality assessment tool).
results We found that depression and cognitive 
impairment were the first symptoms to appear in 98.5% 
and 99.1% of individuals in a study with late-onset AD 
(LOAD) and 9% and 80%, respectively, in early-onset AD 
(EOAD). Memory loss presented early and was experienced 
12 years before the clinically defined AD dementia in the 
LOAD. However, the rapidly progressive late-onset AD 
presented predominantly with 35 non-established focal 
symptoms and signs including myoclonus (75%), disturbed 
gait (66%) and rigidity. These were misdiagnosed as 
symptoms of Creutzfeldt-Jacob disease (CJD) in all the 
cases. The participant with the lowest mini-mental state 
examination score of 25 remained stable for 2 years, 
which is consistent with the score of the healthy family 
members.
conclusions The findings of this review suggest that 
neurological and depressive behaviours are an early 
occurrence in EOAD with depressive and cognitive 
symptoms in the measure of semantic memory and 
conceptual formation in LOAD. Misdiagnosis of rapidly 
progressive AD as CJD and the familial memory score can 
be confounding factors while establishing a diagnosis. 
However, the study was limited by the fact that each one 
of the findings was based on a single study.
IntrOductIOn
Alzheimer’s disease (AD), the most common 
type of dementia, is a devastating disease with 
multiple presentations. While the disease 
is associated with old age, scientists1 2 have 
discovered that disease can develop at any 
age and the reason for this is unclear. The 
disease could develop before the age of 65 
years, known as early-onset AD (EOAD), 
which might be inherited or sporadic, or 
after the age of 65 years, known as late-onset 
AD (LOAD), that accounts for 90% of all AD 
cases.3 In the UK, a prevalence of 520 000 has 
been reported in 20144–6 with high individual, 
healthcare and financial burden.7 8 There 
are challenges in diagnosing the disease 
early,9–11 which can result to non-reversible 
symptoms progression, that lead to institu-
tionalisation and high mortality rate among 
this group.12 There is also the emotional and 
physical burden to the caregivers13 14 as well 
as emotional, physical and financial burden 
to the healthcare system.15 Even though 
there is discourse in the meaning of the early 
diagnosis, here, it refers to the diagnosis at 
the lowest threshold of the disease or at the 
stage of mild cognitive impairment (MCI), 
with cluster of early signs and symptoms and 
the diagnosis of the pathology of the disease 
before dementia. This is because the disease 
has a preclinical stage with the clinical symp-
toms yet evident but with changes in the brain 
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Research
strengths and limitations of this study
 ► The review indicates a paucity of data on the 
study objectives and heterogeneity in the timing of 
symptoms presentation in published studies.
 ► Comprehensive search strategy was used to identify 
articles for this review.
 ► This is the first review to identify the sequence and 
timing of the signs and symptoms in the early stage 
of Alzheimer’s disease.
 ► Dearth of data, heterogeneity in methodology and 
findings made it impossible to draw a definite 
conclusion.
 ► Several other potential sources of heterogeneity like 
age, gender and education could not be investigated 
with the dearth of data.
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and the risk of progression unknown, intermediate stage 
with mild cognitive and functional changes and dementia 
due to AD stage with severe cognitive and functional 
decline.
Among the reasons for the late diagnosis is that the 
signs and symptoms, at the early stages of AD, are some-
times not recognised and/or mistaken for signs of old age 
or symptoms of other conditions.5 16–18 The above may be 
partly due to the fact that the timing and sequence of the 
early presentation of signs and symptoms are not reported 
by current studies.19–21 Delaying onset of the disease by 
5 years through early diagnosis and intervention could 
reduce the mortality rate of dementia (advanced stage of 
AD) by 30 000 yearly.22
This review attempts to answer the following research 
question: how far back from diagnosis and in what 
sequence do the first symptoms that warrant an AD diag-
nosis appear? Further understanding of the timing and 
the sequence of the presentation of signs and symptoms 
may enable practitioners to offer timely intervention.
MethOds
Types of studies
All types of empirical studies were considered, excluding 
those of qualitative design.
Participants
Included participants were aged between 30 and 85 years 
and diagnosed with AD.
settings
Primary care, memory clinics or secondary care settings.
target condition
AD and any subtypes were diagnosed with the following 
tools: (a) National Institute of Neurological and Commu-
nicative Disorders and Stroke AD and Related Disorders 
Association (NINCDS-ADRDA, UK), a commonly used 
criteria for AD dementia; (b) National Institute on 
Aging-Alzheimer’s Association (USA), a more recent 
criteria that use biomarkers to support the diagnosis; (c) 
Diagnostic and Statistical Manual of the American Psychi-
atric Association (DSM-IV)23; and (d) DSM-5.24
Outcomes
The outcomes of this review included (i) the sequence 
of presentation of the signs and symptoms that are indic-
ative of AD prior to diagnosis,20 (ii) the timing from the 
first reported symptom to diagnosis,20 (iii) the timing 
from MCI to diagnosed dementia stage,25 (iv) the timing 
of assessments leading up to a diagnosis of AD26 and (v) 
the timing from clinical presentations to case fatality or 
death.27
Index symptoms
We used an index of early symptoms as a reference to 
ascertain the timing and sequence of events prior to 
disease presentation. The index is based on previous 
studies,28–32 which includes apathy, agitation, anxiety, 
anosognosia, aberrant motor behaviour, acalculia, 
alexia, anomia, disinhibition, depression, irritability, 
hallucination and olfactory disturbances and weight 
loss.28–32
exclusion criteria
 ► Participants with other dementia or other neurologi-
cal conditions;
 ► Inaccurate diagnostic criteria;
 ► Single index symptom;
 ► Late-stage AD (AD dementia); a set of symptoms in-
cluding memory loss, difficulty in thinking, prob-
lem solving or language difficulties.33
Search criteria for identification of studies
We searched the literature via OvidSP MEDLINE (1950), 
PsycINFO (1887), British Nursing Index (1994), CINAHL 
(1937), PubMed central (2000) and the Cochrane 
register for diagnostic and intervention studies. We also 
used ‘snowballing’ and searched the references of rele-
vant articles. Searches covered the period from 1937 to 
May 2016. No language or publication restrictions were 
applied. We used medical subject headings terms to stan-
dardise and improve the search; AD was the main term 
followed by the basic terms timing, onset and country, 
and the combination of terms. Details of the database 
search strategies are presented in online supplementary 
appendix 1.
data collection and analysis
Assessment of methodological quality
The qualities of included studies were assessed using the 
QUADAS-2 tool, a methodological quality assessment tool 
used to assess diagnostic accuracy studies34 (table 1) and 
PRISMA checklist. The tool consists of 14 items that rates 
the risk of bias, source of variations (applicability and 
reporting of quality), with each item rated as ‘yes’, ‘no’ 
or ‘unclear’, tailored under four domains that includes: 
participants selection; index test (signs and symptoms 
interpretation), reference standard (diagnostic criteria 
that correctly classify the target condition) and flow and 
timing (time interval and intervention between index test 
and reference standard).
results
Results of the search
The process by which articles were identified, screened 
and selected for the review is described in figure 1. A total 
of 3528 articles were identified in the databases including 
318 duplicates. Nine others were identified through hand 
searching, and 3179 were excluded based on the review 
of titles and abstract alone. The full-text versions of 40 
were assessed for eligibility, 13 were initially included 
but 9 later excluded (reasons stated below). Four articles 
were finally included in the review.
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Figure 1 Flowchart indicating the process for the selection 
of studies. The flowchart indicates the articles identified 
through the search: those reviewed as title and abstract, 
those reviewed fully and the ones that met the inclusion 
criteria.
reasons for exclusion
Although 13 studies were reviewed in full, 9 were excluded. 
The reasons for exclusion were: four studies were on 
unspecified dementia30 35–37; one study was undertaken in 
a developing country38; another on caregiver’s distress31; 
one study was on a single case22; one study had incom-
plete data,39 while another did not have a reference point 
for the diagnosis of AD.19
summary of findings
Methodological quality of included studies
The methodological quality in each domain was assessed 
individually.
The QUADAS-2 scores for each domain (table 1) of 
the studies included in the review are shown in figures 2 
and 3. The reviewer included a nested case control with 
random sampling,25 longitudinal follow-up of patients 
with MCI,20 longitudinal prospective study of individuals 
at risk of autosomal dominant familial AD (FAD)26 and 
a retrospective case study (postmortem).27 For the case 
studies,20 26 27 the exclusion criteria were appropriate and 
sample selection was consecutive, which reduced the risk 
of selection bias. (table 2, figure 2)
The index test was not influenced by the reference 
standard in three studies.20 25 26 However, the index test 
domain was judged as having a high risk of bias in a study27 
due to the fact that the index tests were interpreted based 
on the knowledge of the disease (postmortem). In the 
applicability concerns, the conduct and interpretation 
of the index symptoms were different from the review 
question in Fox et al26 and Schmidt et al.27 The Fox et al26 
study focused on the mean time from first assessment 
to the appearance of symptoms at reporting, while the 
study published by Schmidt et al27 focused on identifying 
the median time span from clinical presentation of the 
disease to case fatality or death.
In the reference standard domain, all studies were 
undertaken using the diagnostic criteria for AD, 
recognised internationally that could correctly classify 
the condition with masking in all. The Schmidt et al 
study27 on rapidly progressive AD (RPAD) was under-
taken postmortem, the gold standard for the diagnosis 
of AD. However, none of the studies reported how the 
reference standard was operationalised or applied. They 
were assessed as being a low risk of concern about appli-
cability.
In the flow and timing domain, there was an appro-
priate interval between the appearance of symptoms and 
signs and the reference standard. There was no mention 
of treatment in between the timings and all of the partici-
pants were diagnosed using the same reference standard. 
All participants were included in the analysis.
Findings
Outcome I
Of the 148 participants in the Devier et al study,20 39 (26%) 
converted to AD and all of the converters were 55 years 
at baseline, indicating an EOAD. There were differences 
in the first symptom at presentation with memory decline 
reported as the first in 118 (80%) of the cases, depressed 
mood in 13 (9%), declined language in 6 (4%), change 
in performance of higher order/cognitive activities in 
4 (3%), disorientation in 3 (2%), personality changes 
and behavioural changes in 2 (1%), with no group 
difference in symptoms reporting. Sequentially in the 
order of appearance of the signs and symptoms in all the 
participants, memory decline was the first followed by 
performance changes, changes in language, disorienta-
tion, personality changes, depressed mood, behavioural 
changes and psychosis, consecutively. However, for 
depression, reverse causality could be the case, as the 
history of depression with the first onset before the age of 
60 years represents a risk of developing AD in later life40 
and all cause dementia.41
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Figure 2 Graph representing the risk of bias and applicability concerns. Each domain is represented as a percentage across 
included studies for the review; the red colour indicates high risk, while green indicates low risk. However, none of the studies 
were given an unclear risk of bias and applicability concerns (QUADAS-2 tool).
Figure 3 Summary of the risk of bias and applicability concerns. The reviewer’s judgement on each domain for the included 
studies is shown with a high risk of bias and applicability concerns on index test for.32
Outcome II
Memory decline was experienced in 38.5 months 
before diagnosis,20 depressed mood in 37.4 months, 
performance in 36.8 months, personality changes in 
32.5 months, behavioural changes in 31.1 months, 
language difficulties at 29.2 months, disorientation in 
29.1 months and psychosis at 14.0 months prior to the 
diagnosis.
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Outcome III
Amieva et al25 study reported cognitive decline 12 years 
before dementia in a measure of semantic memory and 
conceptual formation. Depressive symptoms appeared 
concomitantly with the cognitive decline and followed 
2 years later with verbal memory decline. Two years later, 
visual disturbances were recorded and worsened until the 
dementia stage.
Outcome IV
Of the 63 subjects in the Fox et al26 study of autosomal 
dominant FAD, 10 converted to probably AD and the 
mean time (±SD) from first assessment to the appearance 
of symptoms was 2.6±1.4 years. Episodic memory loss 
was the most common and noticed on average 6 months 
before symptomatic assessment. The study suggests that 
cognitive decline is present 2–3 years before symptoms 
and 4–5 years before individuals fulfil the criteria for 
probably AD. There was no distinction in presentations 
with regards to age, gender and handedness. Verbal 
memory was superior to semantic memory in differenti-
ating AD from normal ageing, with the lowest score in 
mini-mental state examination (MMSE) of 25 in a partic-
ipant remaining stable for 2 years consistent with family 
members with the same score that remained healthy. This 
could help discriminate individuals at risk of conversion.
Outcome V
Thirty-five distinct neurological, psychiatric and auto-
nomic symptoms and signs were identified in the Schmidt 
et al27 study. The sequence and timing in months (aver-
agely 26.4) of the presentation of the signs and symptoms 
were as follows: disinhibition, 51.1; spasticity, 31.1; 
dysphagia, 21.6; akinetic mutism, 20.0; significant weight 
loss, 20.0; apraxia, 19.5; apathy, 17.0; sleep disorder, 16.0; 
delusions, 15.0; myoclonus, hallucinations, seizures, 13.0; 
impaired concentration, 4.5; depression, 4.0; and disori-
entation, 2.0, with others following thereafter. A third of 
RPAD experienced rapid weight loss and sleep disorder, 
indicating their significance in discriminating the disease 
from other dementias.
signs and symptoms
A pooled estimate was not possible to be reported due 
to the differences in participants, symptoms and types of 
AD, as well the scarcity of research that had reported on 
the sequence and timing of the early signs and symptoms. 
MCI was required at baseline in the Devier et al study,20 
with memory complaints 6 months to 10 years prior to 
enrolment. The study began long before the Petersen42 
MCI criteria definition. Prior to enrolment, memory loss 
was observed on average of 38.5; depressed mood, 37.4; 
performance, 36.8; personality, 32.1; behaviour deficits, 
31.1; language deficits, 29.2; disorientation, 29.1 and 
psychosis, 14.0 months, before diagnosis.
For the 10 converters in the Fox et al study,26 the mean 
time (±SD) from initial assessment to first symptomatic 
assessment was 3.1±1.5 years (range 1–5 years). The 
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most common presentations were symptoms of very 
mild deficit in episodic memory. Two of the 10 subjects 
already had deficits in verbal memory and were the first 
to be symptomatic. Verbal memory deficit was observed 
1–5 years during the symptomatic phase, indicating 
higher early sensitivity than the semantic memory and 
cognitive changes 2–3 years before the symptomatic 
phase. There was no difference observed between cases 
and non-converters in terms of age, gender, handedness 
or MMSE at initial assessment and symptomatic assess-
ment.
In the Schmidt et al27 study, the median disease dura-
tion was 26.4 months and the median age at clinical 
onset was 73 years. The authors were unable to obtain a 
summary of the data from the onset of the symptoms to 
disease diagnosis.
All the studies were diagnosed with the NINCDS-
ADRDA diagnostic criteria and symptoms measured with 
the neuropsychiatry inventory score.
dIscussIOn
Four studies met the inclusion criteria, which had hetero-
geneous objectives, diagnosis and participants. The four 
studies had a total of 593 people who were followed for 
conversion to AD. All the studies assessed the timing of 
the signs and symptoms of AD prior to a formal diagnosis 
and/or case fatality, but with different participants and 
type of AD.
Studies were assessed methodologically with the 
QUADAS-2 tool. Three of the included studies20 26 27 vali-
dated their results via NINCDS-ADRDA and one study27 
via postmortem examination.
Even though there were differences in timing, objec-
tives, participants and type of AD, the Fox et al26 study 
on FAD identified a participant with an MMSE score of 
25/30, the lowest in the group, that remained the same 
for 2 years, similar to family members that remained 
well throughout. This supports the evidence that MMSE 
offers a reasonably good diagnosis and classification of 
AD,43 especially the accuracy of the MMSE baseline score. 
However, critics advised that the measurement should be 
interpreted with caution.44 45 Furthermore, Schmidt et 
al27 discovered additional focal neurological symptoms 
consistent with Creutzfeldt-Jacob disease (CJD); AD was 
misdiagnosed as CJD until the postmortem study proved 
AD as the cause of the presentations. This finding is in 
line with Mega et al29 and Zahodne et al,46 who reported 
that there are measurable behavioural changes in AD and 
suggested that focal neurological symptoms are associ-
ated with poor prognosis.46
Memory disturbances remain the predominant differ-
entiating factor between early AD and normal ageing in 
all of the studies. Verbal memory was more vulnerable 
than non-verbal in the early-onset familial AD.26 The 
memory test for words indicated significant differences in 
scores, 1–5 years before becoming symptomatic, against 
the notion of semantic memory vulnerability.
Depressed symptoms appeared at the same time as cogni-
tive symptoms, and each of these was the first symptom to 
appear in some individuals with LOAD. However, memory 
loss presented early and frequently in this group too.20 40 
The rapidly progressive LOAD42 presented predominantly 
with myoclonus (75%), disturbed gait (66%) and rigidity 
(50%). These symptoms were also early in the presenta-
tion process occurring before apathy. Neurological and 
depressive behavioural presentations are an early occur-
rence in EOAD.20 This calls for further studies to identify 
the sequence and timing of the early signs and symptoms 
preceding the diagnosis, to aid the early detection and 
subsequent diagnosis of AD.
The main limitation of this systematic review was the 
dearth of data and heterogeneity in methodology and 
findings in the included studies. Moreover, pooled esti-
mate or statistical analysis for the signs and symptoms was 
not possible to be calculated and several other potential 
sources of heterogeneity like the age of onset, gender and 
education could not be investigated given the paucity of 
relevant data.
We excluded studies on individual symptoms and 
signs, as well as other types of dementia, where it was not 
possible to isolate AD. Further and rigorous research is 
needed to understand the timing and sequence of the 
appearance of the signs and symptoms that elude to AD 
prior to diagnosis, with the aim of supporting as early an 
AD diagnosis as possible.
cOnclusIOns
There is a proposition of multiple definitions including 
MCI and subjective cognitive decline to capture the 
intermediate stage between ageing and mild cognitive 
changes, which is in line with the effort to diagnose AD 
early, by recognising the signs and symptoms as reliable 
predictive markers of the disease.46
There are currently insufficient published data on the 
sequence and timing of the early signs and symptoms of 
AD. We advocate that more research should be under-
taken in this area.
This review is important to general practitioners, 
researchers, health policymakers, the pharmaceutical 
industry and the public. The review is also of importance 
to neurologists and other practitioners dealing with 
dementing disorders.
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